Vanda Pharmaceuticals Inc.
For the period ended Dec 30, 2025. Filed Dec 31, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Dec 30, 2025 · Filed Dec 31, 2025
Use the contents to explore the available documents and sections.
VNDA$3.82+6.4%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · DRUG INTERACTIONS
DRUG INTERACTIONS
Tradipitant is a CYP3A4 substrate. Strong CYP3A4 inhibitors may increase tradipitant exposure, which may increase the risk of adverse reactions to NEREUS™.
Full Nereus™ Prescribing Information can be found at: https://www.nereus.us
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.